IASO Biotheraputics’ CT120 Granted Orphan Drug Designation by the U.S. FDA

IASO Biotherapeutics and Innovent Biologics to Present New BCMA CAR-T Cell Therapy Data in Oral Presentation at ASH 2021

IASO Biotheraputics Completes Enrollment of First Patient in CT120’s Phase I/II Registrational Clinical Trial

SAN JOSE, Calif.., NANJING, China and SHANGHAI, November 9, 2021 – IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative medicines, today announced that the company’s in-house-developed fully human CD19/CD22 dual-targeted chimeric antigen receptor (CAR)-T cell therapy (CT120) has completed enrollment of the first patient in the phase I/II registrational clinical trial for the treatment of CD19/CD22-positive relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r B-NHL). CT120 is the first fully human dual-targeted CAR-T cell therapy approved to enter the clinical stage. The clinical trial of CT120 in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) will also start soon.

IASO Bio Appoints Industry Veteran Dr. Alan Fu Chief Financial Officer

IASO Biotherapeutics Secures $108 Million Series C Funding to Advance Global Development of Innovative Cell Therapies

IASO Biotherapeutics Publishes Preclinical Results of Its CD5-Targeting CAR-T in Molecular Therapy

IASO Biotherapeutics’ World’s First Fully Human CD19/CD22 Dual-Targeted CAR-T Drug Receives Two IND Clearances, Enters Clinical Trials

PLEASONTON, CALIF., NANJING, and SHANGHAI, July 29, 2021 - IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company advancing the development of novel cell therapies for cancer, today announced the clearance from China’s National Medical Products Administration (NMPA) of two Initial New Drug (IND) applications for CT120, the company’s in-house developed fully human CD19/CD22 dual-targeted chimeric antigen receptor (CAR)-T cell therapy for the treatment of CD19/CD22-positive relapsed/refractory B-cell non-Hodgkin's lymphoma (r/r B-NHL) and relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).

IASO Bio Appoints Dr. David He as Chief Technology Officer and Executive Vice President

a asgdasgasgasgd

IASO Biotherapeutics and Innovent Biologics to Present Updated Data from its Anti-BCMA CAR-T Therapy in Relapsed/Refractory Multiple Myeloma at European Hematology Association (EHA) Congress

PLEASANTON, CALIF., NANJING, CHINA, June 8, 2021 – IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases, and Innovent Biologics, Inc. (“Innovent”, HKEX: 01801) jointly announced to deliver an oral presentation on updated data from the Phase I study of CT103A in patients with relapsed/refractory multiple myeloma (R/R MM) at the European Hematology Association (EHA) Congress, June 9-17, 2021. The presentation will further demonstrate the safety, efficacy, and increased persistence of CT103A.

Clinical trial results of the BCMA CAR-T Co-developed by IASO Biotherapeutics and Innovent commented in American Society of Hematology’s medical journal “Blood”

PLEASANTON, CALIF., NANJING, CHINA, June 3, 2021-—IASO Biotherapeutics (IASO Bio), and Innovent Biologics, Inc. (Innovent, HKEX: 01801), today jointly announced that the results of initial clinical studies on treatment of relapsed or refractory multiple myeloma (R/R MM）in subjects using fully human BCMA-targeting CAR (CT103A), an investigational chimeric antigen receptor (CAR) T-cell therapy co-developed by IASO Bio and Innovent (IASO Bio: CT103A, Innovent: IBI326) was published in “Blood”, a peer-reviewed medical journal specializing in hematology.